Stock Price Quote

MARKSANS PHARMA LTD.

NSE : MARKSANSBSE : 524404ISIN CODE : INE750C01026Industry : Pharmaceuticals & DrugsHouse : Private
BSE109.951 (+0.92 %)
PREV CLOSE ( ) 108.95
OPEN PRICE ( ) 109.05
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 254834
TODAY'S LOW / HIGH ( )108.70 111.40
52 WK LOW / HIGH ( )45.65 122.5
NSE110.051.1 (+1.01 %)
PREV CLOSE( ) 108.95
OPEN PRICE ( ) 110.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 1510450
TODAY'S LOW / HIGH( ) 108.65 111.40
52 WK LOW / HIGH ( )45.8 122.5
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 1992
Management Info
Mark Saldanha - Chairman Mark Saldanha - Managing Director
Registered Office

Address 11th Floor, " Grandeur " Opp. Gundecha Symphony,Veera Desai Extension Road,Oshiwara, Andheri (W),
Mumbai,
Maharashtra-400053

Phone 022- 40012000

Email companysecretary@marksanspharma.com

Website www.marksanspharma.com

Registrars Details
Bigshare Services Pvt Ltd
Office No S6-2, 6th Floor, Pinnacle Business Park,Next to Ahura Centre, Mahakali Caves Road,Andheri (E),Mumbai
Listing : BSE, NSE

NEWS

29Sep Marksans Pharma informs about trading
In terms of Company's code of conduct and SEBI (PIT) regulations, Marksa..
31Aug Marksans Pharma informs about issuance
Marksans Pharma has informed that it has received one request from a sha..
23Aug Marksans Pharma trades higher on the BSE
Marksans Pharma is currently trading at Rs. 113.85, up by 0.75 points or..
23Aug Piramal Enterprises gets nod to raise
Piramal Enterprises has received approval to raise up to Rs 3000 crore t..
22Aug Marksans Pharma informs about disclosu
Pursuant to Regulation 7(2) of Securities and Exchange Board of India (P..

Financials

in Millions
QTR Jun 23 ANNUAL 23
Net Profit441.911028.66
Gross Profit 543.95 1320.35
Operating Profit 593.811523.85
Net Sales 1820.416552.04

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Abbott India (BSE)
peergroup  23159.10 (3.44%)
M.Cap ( in Cr)49211.47
Dr. Reddy's Lab (BSE)
peergroup  5586.75 (2.97%)
M.Cap ( in Cr)93178.48
Sanofi India (BSE)
peergroup  7206.50 (2.09%)
M.Cap ( in Cr)16597.02
Divi's Lab (BSE)
peergroup  3764.75 (2.75%)
M.Cap ( in Cr)99942.28
Alkem Laboratories (BSE)
peergroup  3607.65 (2.41%)
M.Cap ( in Cr)43134.87

Shareholding Pattern

PROMOTERS 43.85%
NON-INSTITUTION 37.59%
MUTUAL FUNDS/UTI 2.79%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%

About Marksans Pharma Ltd.

Marksans Pharma Ltd. was incorporated in the year 1992. Its today's share price is 109.95. Its current market capitalisation stands at Rs 4982.54 Cr. In the latest quarter, company has reported Gross Sales of Rs. 6956.02 Cr and Total Income of Rs.7156.86 Cr. The company's management includes Shailaja Vardhan, Sunny Sharma, Harshavardhan Panigrahi, Abhinna Sundar Mohanty, Digant Mahesh Parikh, Seetharama Raju Buddharaju, Varddhman Vikramaditya Jain, Sandra Saldanha, Mark Saldanha, Mark Saldanha.

It is listed on the BSE with a BSE Code of 524404 , NSE with an NSE Symbol of MARKSANS and ISIN of INE750C01026. It's Registered office is at 11th Floor, " Grandeur " Opp. Gundecha Symphony,Veera Desai Extension Road,Oshiwara, Andheri (W)Mumbai-400053, Maharashtra. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Bhuta Shah & Co LLP, MSKA & Associates, NK Mittal & Associates, VS Lalpuria & Co

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.